MKI67 and breast carcinoma: To identify novel biomarker(s) for predicting response to tamoxifen therapy, we carried out a GWAS of Ki-67 response after tamoxifen therapy of 275 patients with breast cancer who received preoperative tamoxifen monotherapy using HumanOmniExpressExome-8 v1.2.